The Australasian Hepatology Association consensus guidelines for the provision of adherence support to patients with hepatitis C on direct acting antivirals
Open Access
- 1 December 2016
- journal article
- research article
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. ume 10, 2479-2489
Abstract
Background: Hepatitis C is a blood-borne virus primarily spread through sharing of drug-injecting equipment. Approximately 150 million people worldwide and 230,000 Australians are living with chronic hepatitis C infection. In March 2016, the Australian government began subsidizing direct acting antivirals (DAAs) for the treatment of hepatitis C, which are highly effective (95% cure rate) and have few side effects. However, there is limited evidence to inform the provision of adherence support to people with hepatitis C on DAAs including the level of medication adherence required to achieve a cure. Methodology: In February 2016, a steering committee comprising four authors convened an expert panel consisting of six hepatology nurses, a hepatologist, a pharmacist, a consumer with hepatitis C and treatment experience, and a consumer advocate. The expert panel focused on the following criteria: barriers and enablers to DAA adherence; assessment and monitoring of DAA adherence; components of a patient-centered approach to DAA adherence; patients that may require additional adherence support; and interventions to support DAA adherence. The resultant guidelines underwent three rounds of consultation with the expert panel, Australasian Hepatology Association (AHA) members (n=12), and key stakeholders (n=7) in June 2016. Feedback was considered by the steering committee and incorporated if consensus was achieved. Results: Twenty-four guidelines emerged from the evidence synthesis and expert panel discussion. The guidelines focus on the pretreatment assessment and education, assessment of treatment readiness, and monitoring of medication adherence. The guidelines are embedded in a patient-centered approach which highlights that all patients are at risk of nonadherence. The guidelines recommend implementing interventions focused on identifying patients’ memory triggers and hooks; use of nonconfrontational and nonjudgmental language by health professionals; and objectively monitoring adherence. Conclusion: These are the first guidelines to support patients and health professionals in the delivery of clinical care by identifying practical adherence support interventions for patients taking DAAs.Keywords
This publication has 54 references indexed in Scilit:
- Assessment of motivating factors associated with the initiation and completion of treatment for chronic hepatitis C virus (HCV) infectionBMC Infectious Diseases, 2013
- Reliability and validity of a self‐efficacy instrument for hepatitis C antiviral treatment regimensJournal of Viral Hepatitis, 2011
- Medication Adherence: WHO Cares?Mayo Clinic Proceedings, 2011
- Evaluation of Medication Adherence and Quality of Life in Patients With Hepatitis C Virus Receiving Combination TherapyGastroenterology Nursing, 2010
- Effective Treatment of Injecting Drug Users With Recently Acquired Hepatitis C Virus InfectionGastroenterology, 2010
- Diabetes and Poor Disease Control: Is Comorbid Depression Associated With Poor Medication Adherence or Lack of Treatment Intensification?Psychosomatic Medicine, 2009
- Review article: adherence to medication for chronic hepatitis C – building on the model of human immunodeficiency virus antiretroviral adherence researchAlimentary Pharmacology & Therapeutics, 2009
- Adherence to medication in bipolar disorder: a qualitative study exploring the role of patients’ beliefs about the condition and its treatmentBipolar Disorders, 2007
- Literacy, self-efficacy, and HIV medication adherencePatient Education and Counseling, 2007
- Adherence to MedicationNew England Journal of Medicine, 2005